M.J. Sheardown et al., “2,3-Dihydroxh-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: A Neuroprotectant for Cerebral Ischemia,” Science, vol. 247, No. 4942, Feb. 2, 1990, pp. 571-574. |
J.E.F. Reynolds, editor, “Martindale: The Extra Pharmacopoeia,” 29th edition, London: The Pharmaceutical Press, 1989, No. 4541-g, “Levodopa”, pp. 1015-1020. |
J.W. Olney et al., “Brief Communication: Excitotoxicity of L-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's Diseases,” Experimental Neurology, vol. 108, No. 3, Jun. 1990, pp. 269-272. |
T. Klockgether et al., “The AMPA Receptor Antagonist NBQX has Antiparkinsonian Effects in Monoamine-depleted Rats and MPTP-treated Monkeys,” Annals of Neurology, vol. 30, No. 5, Nov. 1991, pp. 717-723. |
P.-A. Löschmann et al., Synergism of the AMPA-antagonist NBQX and the and the NMDA-antganist CPP with L-Dopa in Models of Parkinson's Disease, Journal of Neural Transmission, P-D Sect., vol. 3, 1991, pp. 203-213. |